Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-06
2002-04-09
Trinh, Ba K. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S475000, C549S497000, C549S499000, C549S502000, C549S504000
Reexamination Certificate
active
06369102
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to novel compounds and compositions, and methods of their use in the treatment of glaucoma and ocular hypertension. In particular, the present invention relates to the use of certain substituted tetrahydrofuran analogs of D and F series prostaglandins to treat glaucoma and ocular hypertension.
Glaucoma is a progressive disease which leads to optic nerve damage, and, ultimately, total loss of vision. The causes of this disease have been the subject of extensive studies for many years, but are still not fully understood. The principal symptom of and/or risk factor for the disease is elevated intraocular pressure or ocular hypertension due to excess aqueous humor in the anterior chamber of the eye.
The causes of aqueous humor accumulation in the anterior chamber are not fully understood. It is known that elevated intraocular pressure (“IOP”) can be at least partially controlled by administering drugs which reduce either the production of aqueous humor within the eye, such as beta-blockers and carbonic anhydrase inhibitors, or increase the flow of aqueous humor out of the eye, such as miotics and sympathomimetics.
Most types of drugs conventionally used to treat glaucoma have potentially serious side effects. Miotics such as pilocarpine can cause blurring of vision and other visual side effects, which may lead either to decreased patient compliance or to termination of therapy. Systemically administered carbonic anhydrase inhibitors can also cause serious side effects, such as nausea, dyspepsia, fatigue, and metabolic acidosis, which side effects can affect patient compliance and/or necessitate the termination of treatment. Moreover, some beta-blockers have increasingly become associated with serious pulmonary side effects attributable to their effects on beta-2 receptors in pulmonary tissue. Sympathomimetics may cause tachycardia, arrhythmia and hypertension. There is therefore a continuing need for therapies which control the elevated intraocular pressure associated with glaucoma.
Prostaglandins, which are metabolite derivatives of arachidonic acid, have recently been pursued for possible efficacy in lowering IOP. Arachidonic acid in the body is converted to prostaglandin G
2
, which is subsequently converted to prostaglandin H
2
. Other naturally occurring prostaglandins are derivatives of prostaglandin H
2
. A number of different types of prostaglandins have been discovered including A, B, D, E, F, G, I and J-series prostaglandins (EP 0 561 073 A1). Of interest in the present invention are compounds which are believed to exhibit IOP lowering mechanisms similar to those exhibited by PGD
2
(formula (I)) and PGF
2&agr;
, (formula (II)):
The relationship between prostaglandin DP receptor activation and IOP lowering effects is not well understood. Various publications have reported that DP receptor activation leads to second messenger activation and in particular, to the stimulation of adenylate cyclase and resultant increases in cAMP levels (Thierauch, Prostaglandins and their Receptors: II. Receptor Structure and Signal Transduction,
Journal of Hypertension,
volume 12, pages 1-5 (1994). Regardless of mechanism, PGD
2
has been shown to lower IOP (Nakajima, Effects of Prostaglandin D
2
and its analog, BW245C, on Intraocular Pressure in Humans,
Graefe's Archive Ophthalmology,
volume 229, pages 411-413 (1991)). Thus, it has been of interest in the field to develop synthetic PGD
2
analogs with IOP lowering efficacy.
Synthetic PGD
2
-type analogs have been pursued in the art (
Graefe's Archive Ophthalmology,
volume 229, pages 411-413 (1991)). Though some PGD
2
-type molecules lower IOP, these types of molecules have also been associated with undesirable side effects resulting from topical ophthalmic dosing. Such effects have included an initial increase in IOP, conjunctival hyperemia, increases in microvascular permeability, and increases in eosinophile infiltration (Alm, The Potential of Prostaglandin Derivatives in Glaucoma Therapy,
Current Opinion in Ophthalmology,
volume 4, No. 11, pages 44-50 (1993)).
Similarly, the relationship of prostaglandin FP receptor activation and IOP lowering effects is not well understood. It is believed that FP receptor activation leads to increased outflow of aqueous humor. Regardless of mechanism, PGF
2&agr;
, and some of its analogs have been shown to lower IOP (Giuffre, The Effects of Prostaglandin F
2&agr;
, the Human Eye,
Graefe's Archive Ophthalmology,
volume 222, pages 139-141 (1985); and Kerstetter et al., Prostaglandin F
2&agr;
-1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow,
American Journal of Ophthalmology,
volume 105, pages 30-34 (1988)). Thus, it has been of interest in the field to develop synthetic PGF
2&agr;
analogs with IOP lowering efficacy.
Synthetic PGF
2&agr;
-type analogs have been pursued in the art (
Graefe's Archive Ophthalmology,
volume 229, pages 411-413 (1991)). Though PGF
2&agr;
-type molecules may lower IOP, these types of molecules have also been associated with undesirable side effects resulting from topical ophthalmic dosing. Such effects include an initial increase in IOP, breakdown of the blood aqueous barrier and conjunctival hyperemia (Alm, The Potential of Prostaglandin Derivatives in Glaucoma Therapy,
Current Opinion in Ophthalmology,
volume 4, No.11, pages 44-50 (1993)).
Based on the foregoing, a need exists for the development of molecules that may activate the prostaglandin DP and/or FP receptors, yielding a more efficacious lowering of IOP, while exhibiting fewer or reduced side effects.
An agent which exhibits comparable or improved efficacy, but with reduced side effects when compared to other agents, is said to have an improved therapeutic profile. It is an object of this invention to provide a class of lOP lowering agents with an improved therapeutic profile over endogenous prostaglandins, and methods of their use.
SUMMARY OF THE INVENTION
The present invention is directed to compositions and methods of their use in treating glaucoma and ocular hypertension. In particular, the present invention provides certain classes of substituted tetrahydrofurans which may possess functional DP and/or FP receptor agonist activity, and methods of their use in treating glaucoma and ocular hypertension.
DETAILED DESCRIPTION OF THE INVENTION
It has unexpectedly been found that substituted tetrahydrofurans of the present invention exhibit an improved therapeutic profile in the treatment of glaucoma and ocular hypertension when compared to natural prostaglandins and many of their known analogs. The substituted tetrahydrofurans of the present invention are heptanoic acid derivatives having the following formula (III):
wherein:
R=pharmaceutically acceptable ester moiety, CO
2
R
1
, CONR
7
R
8
, CH
2
OR
9
, or CH
2
NR
10
R
11
, where R
1
=H or cationic salt moiety; R
7
and R
8
are the same or different=H or alkyl; R
9
=H, acyl, or alkyl; and R
10
and R
11
are the same or different=H, acyl, or alkyl; with the proviso that if one of R
10
and R
11
=acyl, then the other=H or alkyl;
n=0 or 2;
wherein:
Y=CH
2
CH═CH (cis olefin), CH═CHCH
2
(cis olefin), or CH
2
CH
2
CH
2
;
Z=C≡C, trans CH═CH, or CH
2
CH
2
;
Y
2
=halogen or alkoxy;
X
2
=O, S, or CH
2
; and
A=cis CH═CH, CH
2
CH
2
, or C≡C;
one of R
2
and R
3
=H, and the other=F or OH, where the OH may be free or functionally modified; or R
2
and R
3
taken together=OCH
2
CH
2
O or double bonded O (carbonyl); and
R
4
=cyclohexyl, linear or branched C
5
-C
7
alkyl, or R
5
, wherein:
R
5
=(CH
2
)
m
Xphenyl or (CH
2
)
p
Z
2
, where X=O or CH
2
; m=1-6; the phenyl is either unsubstituted or substituted with R
6
, where R
6
=halogen, CH
3
, CF
3
, CN, OCH
3
or acetyl; p=0-6; and
wherein:
W=O, CH
2
, CH
2
CH
2
, or CH═CH; and R
6
is as defined above;
Alcon Manufacturing Ltd.
Copeland Barry I.
Trinh Ba K.
LandOfFree
Substituted tetrahydrofuran analogs of prostaglandins as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted tetrahydrofuran analogs of prostaglandins as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted tetrahydrofuran analogs of prostaglandins as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2851629